Skip to main content

Donald Segal, Jerome McElroy, Peter Hraber, Lei Tang, Kenneth Holroyd, Roger Vogel, Wim van Harten, Pieter van der Meer, Jeffrey Jeddeloh, Karin Eastham


Microarray service provider GeneXP Biosciences of Woburn, Mass., has appointed seven members to its newly established scientific advisory board: Steven Gullans, chief scientific officer of US Genomics and associate professor of medicine at Harvard Medical School, who will chair the board; David Evans, head of drug discovery at the Translational Genomics Research Institute; Geoff Ginsburg, vice president for molecular medicine and research strategy of Millennium Pharmaceuticals; Glenn Hoke, president and chief science officer of Dyad Pharmaceuticals; Joshua LaBaer, director of the Harvard Institute of Proteomics at Harvard Medical School; John Quackenbush, an investigator at The Institute for Genomic Research; and Ray Stoll, president of Stoll & Associates and former director of toxicology and safety assessment at Boehringer Ingelheim.

Donald Segal has been appointed president and chief executive officer of Helix BioPharma. He has been executive vice president of Helix since 1995. Segal replaces Jerome McElroy as president. McElroy will remain chairman of the board. Sensium Technologies, a subsidiary of Aurora, Canada-based Helix, has been developing a biochip.

Exagen Diagnostics has appointed Peter Hraber as research scientist, and Lei Tang as research scientist and laboratory operations manager, the Albuquerque, NM-based company said last week. Haber is a computational biologist, and Tang a molecular biologist.

Kenneth Holroyd has stepped down as chief operating officer and executive vice president of Genaera “to actively pursue other business interests,” the Plymouth Meeting, Pa.-based company said last week. He will remain a consultant to the company. Furthermore, Roger Vogel has become Genaera’s acting chief medical officer. He has been consulting for the company since last December.

Orion Genomics has promoted Jeffrey Jeddeloh to be director of biomarker discovery and detection. Jeddeloh’s primary responsibility will be to discover and develop assays for detecting epigenetic biomarkers linked to certain cancers.

Jeddeloh joined Orion from the United States Army where he served as a principal investigator at the US Army Medical Research Institute of Infectious Diseases. He received his PhD in molecular genetics from Washington University in St. Louis.

Karin Eastham will resign as senior vice president, CFO, and treasurer of Diversa after the firm’s annual shareholder meeting in mid-May, San Diego-based Diversa said this week. She will continue to consult for Diversa for a period of time.

Michael Clegg, a professor of genetics at UC Riverside, will become a professor of biological sciences at the UC Irvine in July. He will direct the school’s new Center in Evolutionary Genetics.

Microarray diagnostics startup Agendia of Amsterdam, the Netherlands, has appointed two new directors to its board: Wim van Harten, a professor at the Netherlands Cancer Institute, and Pieter van der Meer of Gilde Investment Management.

Filed under

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.